The finding of extensive cooperative mutations in mutant EGFR gliomas that can influence prognosis and drug treatment response highlights the importance of integrated genomic diagnosis for developing rational, personalized polytherapy strategies in patients to improve survival. Here, EGFR is linked to central nervous system cancer.